Gilead Expands its Oncology Collaboration with Tango for ~$6.3B

Shots: Tango to receive $125M up front, $20M as equity investment, up to $410M/ program as an opt-in, extension, and milestones along with royalties on sales of the products. If Tango opts to co-develop and co-promote the product, the parties will equally split profits/losses and development costs in the US and will receive milestones and …

Gilead Expands its Oncology Collaboration with Tango for ~$6.3B Read More »